 Sialic Acid Binding Ig-like Lectin 3
"Sialic Acid Binding Ig-like Lectin 3" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A 67-kDa sialic acid binding lectin that is specific for MYELOID CELLS and MONOCYTE-MACROPHAGE PRECURSOR CELLS. This protein is the smallest siglec subtype and contains a single immunoglobulin C2-set domain. It may play a role in intracellular signaling via its interaction with SHP-1 PROTEIN-TYROSINE PHOSPHATASE and SHP-2 PROTEIN-TYROSINE PHOSPHATASE.
| Descriptor ID |
D063268
|
| MeSH Number(s) |
D12.776.503.921.400 D23.050.301.264.900.565 D23.101.100.900.565
|
| Concept/Terms |
Sialic Acid Binding Ig-like Lectin 3- Sialic Acid Binding Ig-like Lectin 3
- Sialic Acid Binding Ig like Lectin 3
- CD33 Antigens
- Siglec-3
- CD33 Antigen
- Antigen, CD33
- Glycoprotein gp67
- gp67, Glycoprotein
- Antigens, CD33
|
Below are MeSH descriptors whose meaning is more general than "Sialic Acid Binding Ig-like Lectin 3".
Below are MeSH descriptors whose meaning is more specific than "Sialic Acid Binding Ig-like Lectin 3".
This graph shows the total number of publications written about "Sialic Acid Binding Ig-like Lectin 3" by people in this website by year, and whether "Sialic Acid Binding Ig-like Lectin 3" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 0 | 1 | 1 | | 2013 | 1 | 0 | 1 | | 2014 | 1 | 0 | 1 | | 2016 | 1 | 0 | 1 | | 2021 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Sialic Acid Binding Ig-like Lectin 3" by people in Profiles.
-
Qin H, Yang L, Chukinas JA, Shah N, Tarun S, Pouzolles M, Chien CD, Niswander LM, Welch AR, Taylor N, Tasian SK, Fry TJ. Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design. J Immunother Cancer. 2021 09; 9(9).
-
Ho AP, Ho BE, Berg MP, Gutman JA, Draper NL. Blood type change identifies late dominance reversal of chimerism after double umbilical cord blood transplantation with review of the literature. Transfusion. 2021 03; 61(3):960-967.
-
Vallera DA, Felices M, McElmurry R, McCullar V, Zhou X, Schmohl JU, Zhang B, Lenvik AJ, Panoskaltsis-Mortari A, Verneris MR, Tolar J, Cooley S, Weisdorf DJ, Blazar BR, Miller JS. IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function. Clin Cancer Res. 2016 07 15; 22(14):3440-50.
-
Gleason MK, Ross JA, Warlick ED, Lund TC, Verneris MR, Wiernik A, Spellman S, Haagenson MD, Lenvik AJ, Litzow MR, Epling-Burnette PK, Blazar BR, Weiner LM, Weisdorf DJ, Vallera DA, Miller JS. CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. Blood. 2014 May 08; 123(19):3016-26.
-
Wiernik A, Foley B, Zhang B, Verneris MR, Warlick E, Gleason MK, Ross JA, Luo X, Weisdorf DJ, Walcheck B, Vallera DA, Miller JS. Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition. Clin Cancer Res. 2013 Jul 15; 19(14):3844-55.
-
Jordan CT. Targeting myeloid leukemia stem cells. Sci Transl Med. 2010 May 12; 2(31):31ps21.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|